Loading...
Market
AstraZeneca's China revenue drops significantly in 2025 fiscal year?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
AstraZeneca's official financial reports
Story
AstraZeneca Faces Investigation in China Over Insurance Fraud Involving Tagrisso and Leon Wang
Nov 5, 2024, 10:00 AM
AstraZeneca is under investigation in China, with high-ranking executive Leon Wang and other personnel being scrutinized by authorities. The investigation stems from allegations that AstraZeneca China's sales team falsified genetic test results to ensure state-backed insurance would cover the company's lung cancer drug, Tagrisso. This insurance fraud has reportedly involved dozens of senior executives within the company and has led to prosecutions, as reported by Caixin Global. AstraZeneca's Chinese market, which accounts for approximately 13% of its $5.8 billion in revenue, is now facing significant challenges due to these allegations. Wang Lei, the executive vice president overseeing AstraZeneca’s operations in China, is cooperating with the authorities, though the details of the investigation remain unclear.
View original story
Similar markets
Increase investment in China • 25%
Reduce operations in China • 25%
No change in strategy • 25%
Other strategic response • 25%
Less than 5% increase • 25%
5% to 10% increase • 25%
10% to 15% increase • 25%
More than 15% increase • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Outperforms sector • 25%
Matches sector performance • 25%
Underperforms sector • 25%
Significant volatility • 25%
Increase by over 10% • 25%
Change within +/-10% • 25%
Decrease by 10-20% • 25%
Decrease by over 20% • 25%
Revenue increases • 25%
Revenue decreases • 25%
Revenue remains stable • 25%
Other • 25%
Increase by more than 20% • 25%
Increase by 10%-20% • 25%
Increase by less than 10% • 25%
Decrease • 25%
Top 10 • 25%
Top 20 • 25%
Top 50 • 25%
Not in Top 50 • 25%